Lung Cancers Completed Phase 2 Trials for Topotecan (DB01030)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00365547Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic ChemotherapyTreatment
NCT00193245Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung CancerTreatment
NCT00193388Weekly Topotecan in the Second-Line Treatment of Small Cell Lung CancerTreatment
NCT00193401Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung CancerTreatment
NCT00028925Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung CancerTreatment
NCT00033696Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerTreatment
NCT00004055Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung CancerTreatment
NCT00004137S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung CancerTreatment
NCT00003812Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerTreatment
NCT00003943Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.Treatment
NCT00003281Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung CancerTreatment
NCT00025272Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerTreatment